Home » Authors » Catherine Hollingsworth

Articles by Catherine Hollingsworth

Morphosys Pairs Antibody Platform with Sloning's

Oct. 8, 2010

By Catherine Hollingsworth

NewCo News: Tivorsan Ready to Raise Funds for Biglycan DMD Candidate

Oct. 7, 2010

By Catherine Hollingsworth

Cyclacel Seeks to Raise $22M for Phase III-Ready AML Drug

Oct. 6, 2010

By Catherine Hollingsworth

SPA in Hand, Onconova Moves Estybon into MDS Phase III

Oct. 5, 2010

By Catherine Hollingsworth

AVEO Regains Rights to Phase II Antibody AV-299

Oct. 1, 2010

By Catherine Hollingsworth

MAP Raising $40.9M as Levadex Heads Toward NDA

Sep. 30, 2010

By Catherine Hollingsworth

Researcher's Pet Project Leads to Eye Therapy, Lasker Prize

Sep. 29, 2010

By Catherine Hollingsworth

VaxDesign to be Acquired by Sanofi Pasteur in $60M Deal

Sep. 28, 2010

By Catherine Hollingsworth

Cylene Adds $12M to Top Off Substantial Series C Round

Sep. 24, 2010

By Catherine Hollingsworth

Sanofi-Vical's Gene Therapy Flames Out in Phase III Trial

Sep. 23, 2010

By Catherine Hollingsworth

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 24, 2025.
Regulatory actions for April 24, 2025
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cel-Sci, Novavax,...
Go ask Alis? New fund aims to rescue biopharma’s trapped cash
BioWorld
“They are not zombies, they are fallen angels.” That is view of Nick Johnston, a U.K-based banker who has come up with a new plan to rescue listed companies whose...
Synthetic Design emerges with $20M and next-gen ADC platform
BioWorld
Synthetic Design Lab Inc., which emerged from stealth with a $20 million seed round and a platform technology aimed at advancing the antibody-drug conjugate (ADC)...